MILES' CIPRO ORAL FLUOROQUINOLONE ANTIBIOTIC SURPASSES $ 135 MIL. IN 1988 U.S. SALES
Miles' Cipro oral quinolone sales exceeded $ 135 mil. in the U.S. in 1988, Miles reported as part of a summary of its Bayer USA figures for last year. Calling Cipro (ciprofloxacin) "the most successful introduction of an anti-infective product ever in the U.S. market," Bayer said the product was a major contributor to 17% volume growth by Miles in 1988. The U.S. health care subsidiary logged sales of $ 1.7 bil., up from $ 1.46 bil. in the previous year. According to recent market data, Cipro's growth has been built on a good balance between the outpatient market and institutional use. At a recent review of 1988 prescription drug use trends by Pharmaceutical Data Services (PDS), Cipro sales through retail channels in 1988 were estimated at $ 72 mil. The PDS figure is based on filled prescription data (not manufacturer sales to the trade). It indicates institutional use of the product in 1988 in the $ 60 mil. range. At $ 72 mil. in PDS figures, Cipro exceeded Lilly's long-time cephalosporin leader, Keflex (cephalexin), in 1988 sales. Keflex has been declining sharply in sales due to generic competition. The leading oral antibiotic through retail pharmacy outlets in the U.S. is Lilly's Ceclor (cefaclor), which PDS puts eighth among the top U.S. sellers last year at $ 260 mil. Miles has an I.V. form of the drug pending approval at FDA. The company is also now launching a calcium channel blocker, Nimotop (nimodipine), for a niche indication -- subarachnoid hemorrhage due to ruptured cerebral aneurysm. The company recently began running "coming soon" ads for another calcium channel blocker, nitrendipine (Baypress). To be co-promoted by Roche, that product has been watched as a second generation competitor to Procardia (nifedipine). Nifedipine is licensed to Pfizer in the U.S. by Bayer.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth